Valuation: Valneva SE

Market Cap 531M 609M 501M 455M 853M 58.43B 857M 6.01B 2.32B 29.71B 2.29B 2.24B 95.59B P/E 2026 *
-6.43x
P/E 2027 * 10.1x
Enterprise Value 665M 762M 628M 570M 1.07B 73.15B 1.07B 7.52B 2.9B 37.19B 2.86B 2.8B 120B EV / Sales 2026 *
4.4x
EV / Sales 2027 * 2.09x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day+1.77%
1 week-4.88%
Current month+4.25%
1 month-3.62%
3 months+22.84%
6 months-37.49%
Current year-25.33%
1 week 2.75
Extreme 2.751
2.98
1 month 2.69
Extreme 2.69
3.11
Current year 2.04
Extreme 2.041
5.13
1 year 2.04
Extreme 2.041
5.24
3 years 1.73
Extreme 1.733
7.03
5 years 1.73
Extreme 1.733
29.6
10 years 1.73
Extreme 1.733
29.6
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Change 5-day change 1-year change 3-year change Capi.($)
+1.77%-4.88% - - 609M
+0.11%+2.71%+0.44%+26.85% 46.28B
-1.12%+1.78%+42.30%+27.55% 43.85B
-3.04%-6.29%+338.56%+515.97% 40.93B
-0.74%+1.25%+4.92%+67.98% 39.89B
-0.50%+0.67%+10.29%+41.28% 29.5B
-0.46%+4.22%+22.81%+139.44% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.19%+38.68% 15.22B
-3.14%+31.91%-11.79% - 14.05B
Average -0.87%+3.76%+53.72%+122.54% 29.15B
Weighted average by Cap. -1.09%+1.87%+68.04%+130.90%

Financials

2026 *2027 *
Net sales 151M 173M 143M 129M 243M 16.62B 244M 1.71B 659M 8.45B 651M 636M 27.18B 283M 325M 268M 243M 455M 31.18B 457M 3.2B 1.24B 15.85B 1.22B 1.19B 51.01B
Net income -81.11M -93.02M -76.59M -69.55M -130M -8.93B -131M -917M -354M -4.54B -349M -342M -14.6B 53.07M 60.86M 50.11M 45.51M 85.26M 5.84B 85.62M 600M 232M 2.97B 229M 224M 9.55B
Net Debt 134M 153M 126M 115M 215M 14.71B 216M 1.51B 584M 7.48B 576M 563M 24.07B 62.48M 71.65M 58.99M 53.57M 100M 6.87B 101M 707M 273M 3.5B 269M 263M 11.25B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
18/09/26 EUR 2.824 +1.77% 24,482
17/09/26 EUR 2.775 -1.67% 15,125
16/09/26 EUR 2.822 +0.25% 907
15/09/26 EUR 2.815 -5.54% 7,783
14/09/26 EUR 2.980 +0.37% 7,984
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.800EUR
Average target price
6.193EUR
Spread / Average Target
+121.17%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!